EUCTR2004-002515-89-IT进行中（未招募）不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
BRISTOL-M.SQUIBB0 个研究点目标入组 256 人开始时间: 2005年4月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateRevised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-BEBristol-Myers Squibb International Corporation256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateRevised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14EUCTR2004-002515-89-SEBristol Myers Squibb International Corporation256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateProtocol version 1.0 dated 2004-10-05, andAmendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-ATBristol Myers Squibb International Corporation256
进行中（未招募）
1 期
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib Mesylate.Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-GBBristol-Myers Squibb International Corporation256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateRevised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-DEBristol-Myers Squibb International Corporation256